Novel Tumor-specific Mutations in Receptor Tyrosine Kinase Subdomain IX Significantly Reduce Extracellular Signal-regulated Kinase Activity.

导出原文传递

翻译打印收藏纠错

第一作者： Masakuni,Serizawa

第一单位： Drug Discovery and Development Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

作者： Masakuni,Serizawa ^[1] ; Masatoshi,Kusuhara ^[2] ; Sumiko,Ohnami ^[3] ; Takeshi,Nagashima ^[4] ; Yuji,Shimoda ^[4] ; Keiichi,Ohshima ^[5] ; Tohru,Mochizuki ^[5] ; Kenichi,Urakami ^[3] ; Ken,Yamaguchi ^[6]

作者单位： Drug Discovery and Development Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan. ^[1] Drug Discovery and Development Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan Region Resources Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan m.kusuhara@scchr.jp. ^[2] Cancer Diagnostics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan. ^[3] Cancer Diagnostics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan SRL, Inc., Tokyo, Japan. ^[4] Medical Genetics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan. ^[5] Shizuoka Cancer Center Hospital and Research Institute, Shizuoka, Japan. ^[6]

关键词 FLT3 NTRK1 kinase subdomain IX molecular-targeted cancer therapeutics receptor tyrosine kinase whole-exome sequencing